Enoxaparin Becat
Low molecular weight heparin (LMWH) injection for blood clot prevention and treatment
Enoxaparin Becat is a low molecular weight heparin (LMWH) administered by subcutaneous injection. It is primarily used to prevent and treat blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Enoxaparin works by inhibiting clotting factors in the blood, particularly Factor Xa, to reduce the risk of thrombus formation. This medication is available only by prescription and is commonly used before and after surgical procedures, during hospitalisation, and in the management of acute coronary syndromes.
Quick Facts
Key Takeaways
- Enoxaparin Becat is a low molecular weight heparin used primarily to prevent and treat blood clots (DVT and PE), especially following surgery or during prolonged immobilisation.
- It is administered as a subcutaneous injection, usually into the abdominal wall, and is available in pre-filled syringes for easier dosing and self-administration.
- Bleeding is the most significant risk; patients must report any unusual bruising, blood in urine or stools, or prolonged bleeding to their healthcare provider immediately.
- Enoxaparin should not be used in patients with active major bleeding, heparin-induced thrombocytopenia (HIT), or known allergy to heparin or pork-derived products.
- Regular monitoring of platelet count and renal function may be required, particularly in elderly patients and those with kidney impairment.
What Is Enoxaparin Becat and What Is It Used For?
Enoxaparin Becat belongs to a class of medications known as low molecular weight heparins (LMWHs). These are derived from unfractionated heparin through a controlled depolymerisation process, which yields smaller polysaccharide chains with more predictable pharmacokinetic and pharmacodynamic properties. The active substance, enoxaparin sodium, has a mean molecular weight of approximately 4,500 daltons, distinguishing it from standard unfractionated heparin which has a mean molecular weight of approximately 15,000 daltons.
The primary mechanism of action involves binding to antithrombin III (AT III), a naturally occurring anticoagulant protein in the blood. This binding dramatically enhances the ability of antithrombin III to inhibit Factor Xa, a key enzyme in the coagulation cascade that converts prothrombin to thrombin. Unlike unfractionated heparin, enoxaparin has a higher ratio of anti-Factor Xa to anti-Factor IIa (thrombin) activity, approximately 3.6:1, which contributes to its more predictable anticoagulant response and lower risk of heparin-induced thrombocytopenia.
Enoxaparin Becat is approved for several clinical indications. The most common use is the prevention of venous thromboembolism (VTE) in patients undergoing surgical procedures, particularly orthopaedic surgery such as hip and knee replacement, abdominal surgery, and other procedures that carry a significant risk of blood clot formation. Patients who are immobilised due to acute illness, including heart failure, severe respiratory disease, or acute infections, may also receive enoxaparin for VTE prophylaxis.
In addition to prophylaxis, enoxaparin is used in the treatment of established deep vein thrombosis (DVT), with or without pulmonary embolism. It serves as the initial anticoagulant therapy, often bridging to oral anticoagulants such as warfarin or direct oral anticoagulants (DOACs). Enoxaparin is also an important component in the management of unstable angina and non-ST-elevation myocardial infarction (NSTEMI), where it is administered alongside antiplatelet therapy to reduce the risk of further cardiac events.
The subcutaneous route of administration offers significant practical advantages. After subcutaneous injection, enoxaparin has a bioavailability of approximately 100%, with peak anti-Factor Xa activity occurring 3 to 5 hours after administration. The half-life is approximately 4.5 hours after a single dose, allowing for once- or twice-daily dosing depending on the clinical indication. These properties make enoxaparin suitable for outpatient treatment of DVT and for self-administration by patients who have been trained in injection technique.
What Should You Know Before Taking Enoxaparin Becat?
Contraindications
There are several situations in which Enoxaparin Becat must not be used. Understanding these contraindications is essential for patient safety. Your prescribing physician will evaluate your medical history carefully before initiating therapy.
- Known hypersensitivity (allergy) to enoxaparin sodium, heparin, or any heparin derivative, including other low molecular weight heparins
- Known allergy to pork-derived products (enoxaparin is derived from porcine intestinal mucosa)
- Active clinically significant bleeding, including haemorrhagic stroke
- A history of heparin-induced thrombocytopenia (HIT) within the last 100 days or in the presence of circulating antibodies
- Conditions with a high risk of uncontrolled haemorrhage, including recent haemorrhagic stroke, active peptic ulcer disease, or recent brain, spinal, or ophthalmic surgery
Additionally, enoxaparin should be used with extreme caution in patients with severe hepatic impairment, uncontrolled arterial hypertension, a history of peptic ulcer disease, diabetic retinopathy, or recent neurosurgical or ophthalmic procedures. Patients with prosthetic heart valves, especially pregnant women with mechanical heart valves, require particularly careful management as enoxaparin may not provide adequate anticoagulation in this setting.
Warnings and Precautions
Several important warnings apply to the use of enoxaparin. Spinal or epidural haematoma is a rare but serious complication that can occur in patients receiving enoxaparin who undergo spinal or epidural anaesthesia or spinal puncture. This can result in long-term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters, concomitant use of other drugs affecting haemostasis (such as NSAIDs, platelet inhibitors, or other anticoagulants), and by traumatic or repeated spinal puncture. Patients should be monitored frequently for signs of neurological impairment.
Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated reaction that can occur with any heparin product, including enoxaparin. It typically presents 5 to 10 days after initiation of therapy, with a significant decrease in platelet count (often greater than 50% from baseline). If HIT is suspected, enoxaparin must be discontinued immediately and alternative anticoagulation initiated. Platelet counts should be monitored before treatment and regularly during therapy, particularly in the first three weeks.
Patients with renal impairment require dose adjustment as enoxaparin is primarily cleared by the kidneys. In patients with severe renal impairment (creatinine clearance less than 30 ml/min), exposure to enoxaparin is significantly increased, leading to a higher risk of bleeding. Anti-Factor Xa monitoring may be warranted in this population. Elderly patients are also at increased bleeding risk due to age-related decline in renal function and should be monitored closely.
Low body weight patients (women under 45 kg and men under 57 kg) may experience increased exposure to enoxaparin at prophylactic doses and should be observed carefully for signs and symptoms of bleeding. Obese patients may similarly require dose adjustment or monitoring, as standard doses may provide subtherapeutic anticoagulation.
Pregnancy and Breastfeeding
Enoxaparin does not cross the placenta in significant amounts and is one of the preferred anticoagulants during pregnancy when anticoagulation is clinically indicated. It is commonly prescribed for pregnant women with a history of venous thromboembolism, those with certain inherited or acquired thrombophilias, and women with antiphospholipid syndrome. However, it should only be used when the expected benefit to the mother justifies the potential risk.
Pregnant women receiving enoxaparin require careful planning around delivery. The use of neuraxial anaesthesia (epidural or spinal) requires that enoxaparin be withheld for at least 12 hours after the last prophylactic dose and at least 24 hours after the last therapeutic dose. The multi-dose vial formulation containing benzyl alcohol must be avoided in pregnant women due to the risk of gasping syndrome in neonates.
Limited data suggest that enoxaparin is excreted in breast milk in very small amounts. The oral bioavailability of heparins is extremely low, so the risk to the breastfed infant is considered negligible. Current guidelines generally consider enoxaparin compatible with breastfeeding. However, as with all medications during lactation, the decision should be made in consultation with a healthcare provider, weighing the benefits of anticoagulation against any potential risks to the infant.
How Does Enoxaparin Becat Interact with Other Drugs?
Drug interactions with enoxaparin are primarily related to its anticoagulant effects. Combining enoxaparin with other substances that affect haemostasis can significantly increase the risk of bleeding. Before starting enoxaparin, patients should provide their healthcare provider with a complete list of all prescription medications, over-the-counter drugs, and dietary supplements they are taking.
Major Interactions
The following drug classes represent the most clinically significant interactions with enoxaparin. Concomitant use requires careful clinical monitoring and, in some cases, dose adjustment or avoidance.
| Drug / Class | Interaction Effect | Clinical Management |
|---|---|---|
| Warfarin and oral anticoagulants | Additive anticoagulant effect; significantly increased bleeding risk | Overlap carefully during bridging; monitor INR closely; discontinue enoxaparin when therapeutic INR achieved |
| Aspirin (acetylsalicylic acid) | Inhibits platelet aggregation; increased risk of haemorrhage | Use low-dose aspirin only when specifically indicated (e.g. ACS); monitor for signs of bleeding |
| Clopidogrel, ticagrelor, prasugrel | Potent antiplatelet effect combined with anticoagulation; high bleeding risk | Use combination only when benefits outweigh risks (e.g. ACS with PCI); close monitoring essential |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Impair platelet function and can cause gastrointestinal bleeding | Avoid concomitant use if possible; if necessary, use lowest effective dose for shortest duration |
| Thrombolytics (alteplase, tenecteplase) | Significantly increased risk of major bleeding including intracranial haemorrhage | Used together only in controlled clinical settings (e.g. STEMI); strict protocol adherence required |
| Dextran 40 | Impairs platelet function and coagulation; additive bleeding risk | Avoid concurrent use where possible; if used, monitor closely for haemorrhage |
Minor Interactions
Several other drug classes have less significant but still clinically relevant interactions with enoxaparin. Systemic corticosteroids may increase the risk of gastrointestinal bleeding when combined with anticoagulants. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) can impair platelet function, and their concomitant use with enoxaparin may modestly increase bleeding risk.
Herbal supplements such as ginkgo biloba, garlic supplements, and high-dose fish oil can also affect platelet function and should be used with caution. Patients should inform their healthcare provider about all supplements they are taking. High-dose vitamin E may also potentiate the anticoagulant effect of enoxaparin.
Conversely, protamine sulfate is the antidote for enoxaparin overdose. Protamine partially neutralises the anti-Factor Xa activity of enoxaparin (approximately 60% neutralisation) and almost completely neutralises its anti-Factor IIa activity. This is an important consideration in emergency situations where rapid reversal of anticoagulation is required.
What Is the Correct Dosage of Enoxaparin Becat?
Dosing of Enoxaparin Becat must be individualised based on the clinical indication, patient weight, renal function, and associated risk factors. The drug is administered by subcutaneous injection only (except in certain acute coronary syndrome settings where an initial intravenous bolus may be given). It must never be administered intramuscularly.
| Indication | Dose | Frequency | Duration |
|---|---|---|---|
| DVT prophylaxis (moderate risk surgery) | 2,000 IU (20 mg) | Once daily (SC) | 7–10 days or until mobilisation |
| DVT prophylaxis (high risk / orthopaedic surgery) | 4,000 IU (40 mg) | Once daily (SC) | 4–5 weeks (hip); 2 weeks (knee) |
| DVT prophylaxis (medical patients) | 4,000 IU (40 mg) | Once daily (SC) | 6–14 days |
| Treatment of DVT (with or without PE) | 150 IU/kg (1.5 mg/kg) or 100 IU/kg (1 mg/kg) | Once daily or twice daily (SC) | At least 5 days; overlap with oral anticoagulant |
| Unstable angina / NSTEMI | 100 IU/kg (1 mg/kg) | Twice daily (SC) | 2–8 days (minimum 2 days) |
Adults
For surgical thromboprophylaxis in moderate-risk patients (e.g. general abdominal surgery), the recommended dose is 2,000 IU (20 mg) administered subcutaneously once daily. The first injection is typically given approximately 2 hours before surgery. In high-risk surgical patients, particularly those undergoing orthopaedic procedures such as hip or knee replacement, the dose is increased to 4,000 IU (40 mg) once daily, with the first dose given 12 hours before surgery.
For the treatment of established DVT, the dose is weight-based. Two regimens are accepted: 150 IU/kg (1.5 mg/kg) once daily, or 100 IU/kg (1 mg/kg) twice daily. Both regimens have demonstrated similar efficacy in clinical trials. The once-daily regimen may be preferred for its convenience, particularly in outpatient management. Treatment should continue for a minimum of 5 days and until adequate oral anticoagulation has been established (INR 2.0–3.0 for at least two consecutive days if bridging to warfarin).
In acute coronary syndromes (unstable angina and NSTEMI), the dose is 100 IU/kg (1 mg/kg) twice daily, administered concurrently with aspirin (100–325 mg orally once daily). The recommended duration of treatment is 2 to 8 days, or until clinical stabilisation.
Children
The safety and efficacy of Enoxaparin Becat have not been fully established in the paediatric population. However, enoxaparin is used off-label in paediatrics for the treatment and prophylaxis of thromboembolic disease. Paediatric dosing is weight-based and age-dependent, with neonates and infants typically requiring higher doses per kilogram than older children due to differences in volume of distribution and clearance rates.
Typical paediatric treatment doses range from 100 IU/kg (1 mg/kg) twice daily in older children to 150 IU/kg (1.5 mg/kg) twice daily in neonates and infants under 2 months. Anti-Factor Xa monitoring is essential in paediatric patients to ensure therapeutic levels are achieved, as the dose-response relationship is less predictable than in adults. All paediatric use of enoxaparin should be under the supervision of a paediatric haematologist or equivalent specialist.
Elderly
Elderly patients are at increased risk of bleeding complications with enoxaparin, primarily due to age-related decline in renal function. No specific dose reduction is recommended for elderly patients with normal renal function, but careful monitoring is essential. For patients aged 75 years and over, particularly those with reduced renal function, dose reduction or anti-Factor Xa monitoring should be considered. In the setting of acute STEMI treatment, the recommended dosing for patients over 75 is reduced to 75 IU/kg (0.75 mg/kg) twice daily, without the initial intravenous bolus.
Renal Impairment
Dose adjustment is required in patients with severe renal impairment (creatinine clearance <30 ml/min). For prophylaxis, the dose should be reduced to 2,000 IU (20 mg) once daily. For treatment of DVT or acute coronary syndromes, the dose should be reduced to 100 IU/kg (1 mg/kg) once daily. Anti-Factor Xa monitoring is recommended in all patients with significant renal impairment.
Missed Dose
If you miss a dose of Enoxaparin Becat, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are unsure about what to do, contact your healthcare provider or pharmacist for guidance. Consistent timing of doses is important for maintaining adequate anticoagulation.
Overdose
Overdose with enoxaparin can lead to significant bleeding complications. Accidental overdosage following subcutaneous or intravenous administration may produce haemorrhagic complications. The antidote is protamine sulfate, which is administered intravenously. One milligram of protamine sulfate neutralises approximately 100 IU (1 mg) of enoxaparin if given within 8 hours of the enoxaparin dose. However, even with maximum doses of protamine, anti-Factor Xa activity is never completely neutralised (approximately 60% neutralisation).
If enoxaparin was administered more than 8 hours before the overdose is recognised, or if a second dose of protamine is needed, a smaller infusion of 0.5 mg protamine per 100 IU (1 mg) of enoxaparin may be given. If overdose is suspected, contact your local poison control centre or seek emergency medical attention immediately. Supportive measures, including blood transfusion if necessary, should be initiated as clinically indicated.
What Are the Side Effects of Enoxaparin Becat?
Like all medicines, Enoxaparin Becat can cause side effects, although not everybody experiences them. The most significant adverse effect is bleeding, which can range from minor bruising at the injection site to serious or life-threatening haemorrhage. The risk of bleeding is influenced by dose, duration of therapy, concomitant medications, and patient-specific risk factors such as renal impairment and advanced age.
The following frequency categories are based on clinical trial data and post-marketing surveillance. Patients should be informed about the signs and symptoms of bleeding and instructed to seek immediate medical attention if they experience any concerning symptoms.
Very Common
- Bleeding (haemorrhage) — including surgical site bleeding and bleeding from any anatomical site
- Elevated liver transaminases (AST, ALT) — usually asymptomatic and reversible
- Injection site reactions — bruising, haematoma, pain, or tenderness at the injection site
Common
- Thrombocytosis (elevated platelet count)
- Injection site swelling, inflammation, or induration
- Urticaria (hives), pruritus (itching), and erythema (redness) at injection site
- Minor bleeding (ecchymosis, petechiae, epistaxis, haematuria)
Uncommon
- Thrombocytopenia (decreased platelet count)
- Allergic reactions (rash, urticaria)
- Injection site necrosis
- Headache
Rare
- Heparin-induced thrombocytopenia (HIT type II) — serious immune-mediated condition
- Spinal or epidural haematoma — in patients receiving neuraxial anaesthesia
- Anaphylactic or anaphylactoid reactions
- Skin necrosis at the injection site or distant from the injection site
- Cutaneous vasculitis
- Osteoporosis (with prolonged use, typically greater than 3 months)
- Hyperkalaemia (elevated potassium levels due to aldosterone suppression)
- Alopecia (hair loss)
- Signs of severe bleeding: blood in urine (haematuria), blood in stools (melaena), unexplained extensive bruising, vomiting blood, or prolonged nosebleeds
- Signs of spinal haematoma (if you have had spinal anaesthesia): back pain, numbness or weakness in the legs, bowel or bladder dysfunction
- Signs of severe allergic reaction: difficulty breathing, swelling of face or throat, rapid heartbeat, severe dizziness
- Chest pain, sudden shortness of breath, or coughing up blood (may indicate pulmonary embolism)
Injection site reactions can be minimised by proper injection technique. Patients should alternate injection sites between the left and right anterolateral or posterolateral abdominal wall. The needle should be inserted into a skin fold held between the thumb and forefinger, and the skin fold should be maintained throughout the injection. The injection site should not be rubbed after administration, as this can increase bruising.
Prolonged use of enoxaparin (typically exceeding 3 months) has been associated with an increased risk of osteoporosis. This is a concern particularly for pregnant women who require extended anticoagulation. Patients on long-term therapy should discuss bone health monitoring with their healthcare provider. Adequate calcium and vitamin D intake, as well as weight-bearing exercise when appropriate, may help mitigate this risk.
How Should You Store Enoxaparin Becat?
Proper storage of Enoxaparin Becat is essential to ensure the medication remains effective and safe to use. The pre-filled syringes should be stored at a temperature below 25°C (77°F). The medication must not be frozen, as freezing can alter the molecular structure of the enoxaparin and compromise its efficacy. If the solution has been accidentally frozen, it should be discarded and not used.
Keep the pre-filled syringes in their original packaging until ready for use to protect the medication from light exposure. Before administration, visually inspect the solution. Enoxaparin Becat should be a clear, colourless to pale yellow solution. Do not use the medication if the solution appears cloudy, contains visible particles, or if the syringe appears damaged or has been previously opened.
Do not use Enoxaparin Becat after the expiry date printed on the carton and syringe label. The expiry date refers to the last day of that month. Once removed from the original packaging, the pre-filled syringe should be used promptly. Keep this medication out of the sight and reach of children. Do not dispose of used syringes in household waste; use a sharps disposal container and return full containers to your pharmacy or healthcare provider for proper medical waste disposal.
What Does Enoxaparin Becat Contain?
Each pre-filled syringe of Enoxaparin Becat contains the following:
Enoxaparin sodium 2,000 IU anti-Xa activity (equivalent to 20 mg) per 0.2 ml solution for injection.
Excipient(s): Water for injections. The pre-filled syringe formulation does not contain benzyl alcohol or other preservatives, making it suitable for use in neonates and pregnant women where the multi-dose vial formulation (which may contain benzyl alcohol) would not be appropriate.
Enoxaparin sodium is obtained by alkaline depolymerisation of the benzyl ester of heparin derived from porcine intestinal mucosa. It is a low molecular weight heparin with a mean molecular weight of approximately 4,500 daltons (range 3,800–5,000 daltons). The degree of sulfation is approximately 2.0 per disaccharide unit. Patients with known allergies to pork or pork-derived products should not use this medication.
The pre-filled syringes are equipped with an automatic needle safety device to reduce the risk of needlestick injuries after use. The solution should be clear, colourless to pale yellow. The pH of the solution is between 5.5 and 7.5. Each syringe is for single use only and any unused solution should be discarded appropriately.
Frequently Asked Questions About Enoxaparin Becat
Enoxaparin Becat is a low molecular weight heparin (LMWH) used primarily for the prevention of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly after surgery. It is also used in the treatment of existing DVT and PE, unstable angina, and non-ST-elevation myocardial infarction (NSTEMI). The drug works by inhibiting blood clotting factors, primarily Factor Xa, to reduce the risk of dangerous blood clot formation.
Enoxaparin Becat is administered as a subcutaneous injection, typically into the abdominal wall. The patient should lie down, and the injection is given into the fatty tissue of the abdomen, alternating sides with each dose. Pinch a fold of skin between your thumb and forefinger, insert the needle at a 90-degree angle, and inject the full contents of the syringe while maintaining the skin fold. Do not rub the injection site afterward, as this can increase bruising. Patients can be trained to self-administer these injections at home.
The most common side effects include bleeding (which can occur at any site), injection site reactions such as bruising, pain, or hardness at the injection site, and elevated liver enzymes (transaminases). These liver enzyme changes are usually temporary and resolve after discontinuation. Serious but rare side effects include heparin-induced thrombocytopenia (HIT), spinal or epidural haematoma in patients with spinal procedures, and severe allergic reactions. Contact your doctor immediately if you experience unusual bleeding, signs of allergic reaction, or neurological symptoms.
Enoxaparin does not cross the placenta in significant amounts and is one of the preferred anticoagulants during pregnancy when anticoagulation is indicated. It is commonly prescribed for pregnant women who require anticoagulation, such as those with a history of venous thromboembolism or certain thrombophilic conditions. However, it should only be used under close medical supervision. Pregnant women should use the preservative-free pre-filled syringe formulation to avoid benzyl alcohol exposure. Careful planning around delivery is needed regarding timing of doses and epidural anaesthesia.
The duration depends on the type of surgery and your individual risk factors. After major orthopaedic surgery such as hip replacement, treatment typically continues for 4 to 5 weeks. After knee replacement, prophylaxis usually lasts about 2 weeks. After abdominal or general surgery, prophylaxis usually lasts 7 to 10 days or until you are fully mobile. For acutely ill medical patients, the typical duration is 6 to 14 days. Your doctor will determine the appropriate duration based on your specific risk profile and the type of procedure performed.
Enoxaparin Becat contains the same active substance (enoxaparin sodium) as other branded enoxaparin products. It is approved by regulatory authorities after demonstrating bioequivalence with the reference product. All approved enoxaparin products meet the same quality, safety, and efficacy standards. The choice between different brands is typically based on availability and cost considerations. If your pharmacy substitutes one brand for another, the clinical effect should be equivalent.
References
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Summary of Product Characteristics: Enoxaparin sodium. EMA Product Information. Available at: www.ema.europa.eu
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Available at: www.who.int
- British National Formulary (BNF). Enoxaparin sodium. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Hirsh J, Bauer KA, Donati MB, et al. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S-159S. doi:10.1378/chest.08-0689
- Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-e43S.
- Bates SM, Rajasekhar A, Engelman DT, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances. 2018;2(22):3317-3359.
- U.S. Food and Drug Administration (FDA). Prescribing Information: Enoxaparin Sodium Injection. Available at: www.fda.gov
About Our Medical Editorial Team
This article has been written and reviewed by our team of licensed medical professionals with expertise in hematology, clinical pharmacology, and internal medicine. All content follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, and ACCP.
iMedic Medical Editorial Team — specialists in pharmacology and evidence-based medicine with documented academic background and clinical experience.
iMedic Medical Review Board — independent panel of board-certified physicians who verify all clinical claims against current international guidelines and peer-reviewed literature.
Conflict of Interest Statement: iMedic receives no pharmaceutical company funding or advertising revenue. All editorial content is independently produced without commercial influence.
Last medical review: | Published: